Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has been given an average rating of "Moderate Buy" by the nine research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $5.40.Get Context Therapeutics alerts:CNTX has been the subject of a number of analyst reports. Cantor Fitzgerald began coverage on shares of Context Therapeutics in a research report on Thursday, October 2nd. They issued an "overweight" rating for the company. Guggenheim began coverage on shares of Context Therapeutics in a research note on Thursday, September 18th. They set a "buy" rating and a $5.00 price objective for the company. HC Wainwright raised their price objective on Context Therapeutics from $4.00 to $5.00 and gave the company a "buy" rating in a report on Thursday, November 6th. Wall Street Zen upgraded Context Therapeutics to a "sell" rating in a report on Saturday, November 22nd. Finally, D. Boral Capital reissued a "buy" rating and set a $9.00 price target on shares of Context Therapeutics in a research report on Thursday, November 6th.Get Our Latest Stock Report on CNTXContext Therapeutics Stock PerformanceNASDAQ CNTX opened at $1.12 on Thursday. Context Therapeutics has a 52 week low of $0.49 and a 52 week high of $1.55. The stock's 50 day moving average price is $1.17 and its two-hundred day moving average price is $0.92. The stock has a market capitalization of $102.91 million, a price-to-earnings ratio of -4.67 and a beta of 1.94. Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01). On average, equities research analysts forecast that Context Therapeutics will post -0.51 EPS for the current year. Institutional Investors Weigh In On Context TherapeuticsSeveral large investors have recently made changes to their positions in CNTX. Clear Harbor Asset Management LLC increased its holdings in Context Therapeutics by 60.5% during the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company's stock worth $90,000 after buying an additional 35,000 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Context Therapeutics in the third quarter valued at $100,000. Finally, Vanguard Group Inc. grew its position in shares of Context Therapeutics by 4.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company's stock valued at $3,387,000 after acquiring an additional 134,449 shares during the period. Institutional investors and hedge funds own 14.03% of the company's stock. About Context Therapeutics (Get Free Report)Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.Further ReadingFive stocks we like better than Context TherapeuticsBest Stocks Under $5.00Post 35% Surge, Analysts Eye More Upside in Copper Giant FreeportShould You Invest in Penny Stocks?Why a SpaceX IPO Could Be a Major Catalyst for GOOGL StockManufacturing Stocks InvestingCan Upwork Maintain Its Comeback? Reasons to Be Bullish and BearishThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Context Therapeutics Right Now?Before you consider Context Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.While Context Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here